Michael D. Dake

Dr. Michael D. Dake

Department of Medical Imaging, University of Arizona Health System, Tucson, AZ, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RSRachna T. Shroff
Rachna T. Shroff
PCPavani Chalasani
Pavani Chalasani
RWRan Wei
Ran Wei
DPDaniel Pennington
Daniel Pennington
GQGrace Quirk
Grace Quirk
DBDeepta Bhattacharya
Deepta Bhattacharya

12 August 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
NLNathan L. Liang
Nathan L. Liang
MDMichael D. Dake
Michael D. Dake
MFMichael P. Fischbein
Michael P. Fischbein
JBJoseph E. Bavaria
Joseph E. Bavaria
NDNimesh D. Desai
Nimesh D. Desai
MMMichel S. Makaroun
Michel S. Makaroun

1 November 2021 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MDMichael D. Dake
Michael D. Dake
MFMichael P. Fischbein
Michael P. Fischbein
JBJoseph E. Bavaria
Joseph E. Bavaria
NDNimesh D. Desai
Nimesh D. Desai
GOGustavo Oderich
Gustavo Oderich
HPHimanshu J. Patel
Himanshu J. Patel

9 September 2019 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
MDMichael D. Dake
Michael D. Dake
GAGary M. Ansel
Gary M. Ansel
MBMarc Bosiers
Marc Bosiers
AHAndrew Holden
Andrew Holden
OIOsamu Iida
Osamu Iida
TZThomas Zeller
Thomas Zeller
Purpose: Patient-level data from two large studies of the Zilver PTX drug-eluting stent (DES) with long-term follow-up and concurrent non-drug comparator groups were analyzed to determine whether there was an increased mortality risk due to paclitaxel. Methods: Data from the Zilver PTX randomized controlled trial (RCT) and Zilver PTX and bare metal stent (BMS) Japan post-market surveillance studies were analyzed. Five-year follow-up is complete in both DES studies; follow-up for the BMS study was limited to 3 years and is complete. Kaplan–Meier analyses assessed mortality. A Cox proportional hazards model identified significant factors related to mortality. Results: In the RCT, there were 336 patients treated with the DES and 143 patients treated with percutaneous transluminal angioplasty (PTA) or BMS. In Japan, there were 904 DES patients and 190 BMS patients. There was no difference in all-cause mortality for the DES compared to PTA/BMS in the RCT (19.1% DES versus 17.1% PTA/BMS through 5 years, p = 0.60) or Japan (15.8% DES versus 15.3% BMS through 3 years, p = 0.89). Cox proportional hazard models revealed that age, tissue loss, and congestive heart failure were significantly associated with mortality in the RCT, and critical limb ischemia, age, renal failure, and gender were significantly associated with mortality in Japan (all p < 0.05). Neither treatment with Zilver PTX (p = 0.46 RCT, p = 0.49 Japan) nor paclitaxel dose (p = 0.86 RCT, p = 0.07 Japan) was associated with mortality. Conclusion: Analyses of the Zilver PTX patient-level data demonstrated no increase in long-term all-cause mortality. Level of Evidence: Zilver PTX RCT: Level 1, randomized controlled trial; Japan PMS studies: Level 3, post-market surveillance study.

1 February 2020 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
TMTimothy P. Murphy
Timothy P. Murphy
AKAlbrecht H. Krämer
Albrecht H. Krämer
MDMichael D. Dake
Michael D. Dake
LSLuke E. Sewall
Luke E. Sewall
MCMichael A. Curi
Michael A. Curi
PPPatrick Peeters
Patrick Peeters
To report final 2-year outcomes with the Sentry bioconvertible inferior vena cava (IVC) filter in patients requiring temporary protection against pulmonary embolism (PE). In a prospective multicenter trial, the Sentry filter was implanted in 129 patients with documented deep vein thrombosis (DVT) and/or PE (67.5%) or who were at temporary risk of developing DVT/PE (32.6%). Patients were monitored and bioconversion status ascertained by radiography, computed tomography (CT), and CT venography through 2 years. The composite primary 6-month endpoint of clinical success was achieved in 97.4% (111/114) of patients. The rate of new symptomatic PE was 0% (n = 126) through 1 year and 2.4% (n = 85) through the second year of follow-up, with 2 new nonfatal cases at 581 and 624 days that were adjudicated as not related to the procedure or device. Two patients (1.6%) developed symptomatic caval thrombosis during the first month and underwent successful interventions without recurrence. No other filter-related symptomatic complications occurred through 2 years. There was no filter tilting, migration, embolization, fracture, or caval perforation and no filter-related deaths through 2 years. Filter bioconversion was successful for 95.7% (110/115) of patients at 6 months, 96.4% (106/110) of patients at 12 months, and 96.5% (82/85) of patients at 24 months. Through 24 months of follow-up, there was no evidence of late-stage IVC obstruction or thrombosis after filter bioconversion or of thrombogenicity associated with retracted filter arms. The Sentry IVC filter provided safe and effective protection against PE, with a high rate of intended bioconversion and a low rate of device-related complications, through 2 years of follow-up.

1 June 2021 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
YOYukihisa Ogawa
Yukihisa Ogawa
AWA. Claire Watkins
A. Claire Watkins
BLBharathi Lingala
Bharathi Lingala
INItoga Nathan
Itoga Nathan
PCPeter Chiu
Peter Chiu
MDMichael D. Dake
Michael D. Dake